International heart journal最新文献

Covered Stent Treatment of a Left Circumflex Posterolateral Branch Aneurysm. 覆膜支架治疗左旋后外侧支动脉瘤。

IF 1.4 4区医学

International heart journal Pub Date : 2026-07-31 Epub Date: 2026-07-14 DOI: 10.1536/ihj.26-119

Tetsuro Nagao, Riku Arai, Koichiro Hori, Katsunori Fukumoto, Yasuo Okumura

引用次数: 0

Pseudo-Hypertrophy. Pseudo-Hypertrophy。

IF 1.4 4区医学

International heart journal Pub Date : 2026-07-31 Epub Date: 2026-07-14 DOI: 10.1536/ihj.26-188

Kenichi Inoue, Takumi Hatta, Ryuta Watanabe, Keisuke Kojima, Yasuo Okumura

引用次数: 0

A Giant Saccular Cavo-Tricuspid Isthmus Pouch in a Patient with Common Atrial Flutter. 常见心房扑动患者的巨大囊状腔-三尖瓣峡袋。

IF 1.4 4区医学

International heart journal Pub Date : 2026-07-31 Epub Date: 2026-07-14 DOI: 10.1536/ihj.26-022

Daisuke Yoshida, Masao Takemoto, Eiji Nyuta, Takuya Tsuchihashi

引用次数: 0

Efficacy of 15 mg Edoxaban on Long-Term Outcome after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and High Bleeding Risk. 15mg依多沙班对房颤高危患者经皮冠状动脉介入治疗后远期疗效的影响。

IF 1.4 4区医学

International heart journal Pub Date : 2026-07-31 Epub Date: 2026-07-14 DOI: 10.1536/ihj.25-558

Takao Sato, Yoshifusa Aizawa, Toshihiro Miyamoto, Ryoma Fukuoka, Kazumasa Sugimoto, Yoko Tanimoto, Takashi Nakayama, Kojiro Tanimoto, Koichiro Sugimura, Yoshihide Fujimoto, Takahiko Kiyooka, Akio Kawamura

{"title":"Efficacy of 15 mg Edoxaban on Long-Term Outcome after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and High Bleeding Risk.","authors":"Takao Sato, Yoshifusa Aizawa, Toshihiro Miyamoto, Ryoma Fukuoka, Kazumasa Sugimoto, Yoko Tanimoto, Takashi Nakayama, Kojiro Tanimoto, Koichiro Sugimura, Yoshihide Fujimoto, Takahiko Kiyooka, Akio Kawamura","doi":"10.1536/ihj.25-558","DOIUrl":"10.1536/ihj.25-558","url":null,"abstract":"In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) plus oral anticoagulants increase bleeding risk. Low-dose edoxaban (15 mg) is safe for high-risk older patients with AF; however, its role after PCI compared with the standard 30 mg dose remains unclear. We aimed to compare outcomes of 15 mg and 30 mg edoxaban after PCI.We retrospectively analyzed data from patients with AF undergoing PCI for acute coronary syndrome who received edoxaban 30 mg (n = 99) or 15 mg (n = 49). During admission, DAPT was transitioned to P2Y12 inhibitor monotherapy. Bleeding and thrombotic events were assessed over 2 years, alongside CHADS2, HAS-BLED, and CREDO-Kyoto scores.Compared with 30 mg edoxaban, patients on 15 mg edoxaban were older (86 ± 2 versus 80 ± 6 years, P< 0.01) and had lower hemoglobin levels and body mass index (19.4 ± 3.1 versus 22.7 ± 2.7, P < 0.01) but higher CHADS2 (3.3 ± 0.9 versus 2.8 ± 0.9, P < 0.01), HAS-BLED (3.2 ± 0.9 versus 2.6 ± 0.6, P < 0.01), and CREDO-Kyoto thrombotic and bleeding (5.0 ± 1.1 versus 4.0 ± 1.8, P < 0.01; and 4.1 ± 1.7 versus 2.7 ± 1.2, P < 0.01, respectively) scores. Major bleeding, including clinically relevant non-major bleeding, was more frequent in the 30 mg group (19.7% versus 6.8%, P = 0.08); thrombotic events were comparable (7.4% versus 3.0%, P = 0.35).In weighted Cox analysis, 15 mg edoxaban showed numerically lower hazard ratios for thrombotic (HR: 0.12, 95% CI: 0.01-1.17; P = 0.09) and bleeding (HR: 0.24, 95% CI: 0.06-1.29; P = 0.07) events compared with 30 mg, although these differences did not reach statistical significance.Among older high bleeding-risk patients with AF undergoing PCI, 15 mg edoxaban did not demonstrate superiority over 30 mg with respect to thrombotic or bleeding outcomes.","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"298-305"},"PeriodicalIF":1.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitor in Heart Transplant Recipients with Chronic Kidney Disease. 葡萄糖共转运蛋白2抑制剂钠在慢性肾病心脏移植受者中的疗效和安全性。

IF 1.4 4区医学

International heart journal Pub Date : 2026-07-31 Epub Date: 2026-07-14 DOI: 10.1536/ihj.26-205

Satoru Ando, Masaki Tsuji, Shun Kitamura, Kei Morishita, Saki Kaneko, Nanase Hori, Junichi Ishida, Eisuke Amiya, Masahiko Ando, Masaru Hatano, Minoru Ono, Norihiko Takeda

{"title":"Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitor in Heart Transplant Recipients with Chronic Kidney Disease.","authors":"Satoru Ando, Masaki Tsuji, Shun Kitamura, Kei Morishita, Saki Kaneko, Nanase Hori, Junichi Ishida, Eisuke Amiya, Masahiko Ando, Masaru Hatano, Minoru Ono, Norihiko Takeda","doi":"10.1536/ihj.26-205","DOIUrl":"10.1536/ihj.26-205","url":null,"abstract":"Chronic kidney disease (CKD) is a major long-term complication following heart transplantation (HT). The safety and efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for HT recipients with CKD remains unclear. We retrospectively reviewed the records of HT recipients who were followed up between April 2017 and December 2024 at our hospital; those with CKD who initiated SGLT2i at least 6 months after HT and had available follow-up data for 6 subsequent months were included. Among 91 patients who initiated SGLT2i, 45 were eligible (median age: 50 [47-59] years; 11 (24.4%) female). The median estimated glomerular filtration rate (eGFR) at SGLT2i initiation was 42.9 [33.8-50.6] mL/minute/1.73 m2. All patients continued SGLT2i without adverse events. Relative change in eGFR improved significantly from -9.1% in the 6 months before SGLT2i to +3.7% in the 6 months after (P = 0.043). Uric acid and hemoglobin levels improved (P < 0.001 and 0.002, respectively). Patients were stratified into 2 groups based on the relative change in eGFR to identify factors associated with improvement: those with a positive change (n = 23) and those without (n = 22). In logistic regression analysis adjusting for age and sex, lower eGFR (odds ratio: 1.09, 95% confidence interval: 1.02-1.15, P = 0.013) and non-ischemic etiology of heart failure (odds ratio: 18.9, 95% confidence interval: 1.66-215.0, P = 0.018) were associated with eGFR improvement after SGLT2i initiation. SGLT2i use appears safe and helps prevent CKD progression in HT recipients with CKD.","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"342-348"},"PeriodicalIF":1.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGLT2 Inhibitor Use and Outcomes in Patients with Acute Heart Failure and Low Body Mass Index. SGLT2抑制剂在急性心力衰竭和低体重指数患者中的使用和结局

IF 1.4 4区医学

International heart journal Pub Date : 2026-07-31 Epub Date: 2026-07-14 DOI: 10.1536/ihj.26-100

Yusuke Uemura, Toru Kondo, Yuta Ozaki, Shingo Kazama, Kazuhisa Sawada, Shinji Ishikawa, Kenji Takemoto, Toyoaki Murohara, Masato Watarai

{"title":"SGLT2 Inhibitor Use and Outcomes in Patients with Acute Heart Failure and Low Body Mass Index.","authors":"Yusuke Uemura, Toru Kondo, Yuta Ozaki, Shingo Kazama, Kazuhisa Sawada, Shinji Ishikawa, Kenji Takemoto, Toyoaki Murohara, Masato Watarai","doi":"10.1536/ihj.26-100","DOIUrl":"10.1536/ihj.26-100","url":null,"abstract":"Sodium-glucose cotransporter 2 inhibitors (SGLT2is) improve clinical outcomes in patients with heart failure (HF) with a broad range of body mass indices (BMIs); however, concerns remain regarding their tolerability, safety, and clinical outcomes in patients with extremely low BMI.Patients hospitalized for acute HF at a single center between 2021 and 2023 were retrospectively evaluated. Low BMI was defined as < 18.5 kg/m2 for patients < 70 years and < 20 kg/m2 for those ≥ 70 years. We assessed the clinical characteristics, SGLT2i prescription at discharge, discontinuation within 1 year, and clinical outcomes, including cardiovascular death, HF readmission, and all-cause mortality, were assessed. Time-to-event analyses and inverse probability of treatment weighting (IPTW) were performed.Of 621 patients (median age: 81 years), 29.0% had a low BMI and 35.6% received a SGLT2i at discharge. SGLT2is were prescribed significantly less frequently in patients with low BMI (22.1% versus 41.5%, P < 0.001). Kaplan-Meier analysis showed that the overall 1-year discontinuation-free rate was 0.880, with no significant difference between the BMI groups. In crude analyses, SGLT2i use was associated with lower cardiovascular event rates in the non-low BMI group and lower all-cause mortality in the low BMI group; however, after IPTW adjustment, the latter association was attenuated.SGLT2is were underutilized in patients with HF and low BMI, yet discontinuation and adverse outcomes were not increased. These findings suggest that low BMI alone should not be a reason to avoid or discontinue SGLT2is in patients with acute HF.","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"325-332"},"PeriodicalIF":1.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Percutaneous Coronary Intervention for Coronary Events during Tyrosine Kinase Inhibitor Therapy in Leukemia Patients. 白血病患者酪氨酸激酶抑制剂治疗期间冠脉事件的经皮冠状动脉介入治疗。

IF 1.4 4区医学

International heart journal Pub Date : 2026-05-30 Epub Date: 2026-05-16 DOI: 10.1536/ihj.26-033

Asaki Saijo, Tetsuo Yamaguchi, Akinori Konishi, Yuki Maze, Chinatsu Komiyama, Ayako Harima, Yo Fujimoto, Takahide Kodama

引用次数: 0

Clinical Characteristics of Dynapenia and Sarcopenia in Hospitalized Patients with Cardiovascular Disease. 心血管疾病住院患者动力减少和肌肉减少的临床特点。

IF 1.4 4区医学

International heart journal Pub Date : 2026-05-30 Epub Date: 2026-05-16 DOI: 10.1536/ihj.25-730

Keisuke Okano, Hironori Takami, Kouki Sano, Yusuke Seto, Ritsu Nisimura, Tetsuya Takahashi, Yo Mukai

{"title":"Clinical Characteristics of Dynapenia and Sarcopenia in Hospitalized Patients with Cardiovascular Disease.","authors":"Keisuke Okano, Hironori Takami, Kouki Sano, Yusuke Seto, Ritsu Nisimura, Tetsuya Takahashi, Yo Mukai","doi":"10.1536/ihj.25-730","DOIUrl":"10.1536/ihj.25-730","url":null,"abstract":"Dynapenia, defined as reduced muscle strength despite preserved muscle mass, is increasingly being recognized alongside sarcopenia in older adults. Clinical differences between dynapenia and sarcopenia in hospitalized cardiovascular disease (CVD) patients remain unclear. This study aimed to compare the clinical characteristics among Normal, Dynapenia, and Sarcopenia phenotypes.This prospective, single-center cohort study included patients admitted to the cardiology ward at Seirei Hamamatsu General Hospital (July 2024-September 2025) who received physical therapy and completed body composition assessment at discharge. The patients were divided into Normal, Dynapenia, and Sarcopenia groups classified using a previously reported flowchart and cutoff values for grip strength and skeletal muscle mass index (SMI) based on the Asian Working Group for Sarcopenia 2025 criteria. Three-group comparisons were conducted using multiple comparison methods, and no adjustment was made due to the exploratory nature of the analyses. Adjusted comparisons were conducted using analysis of covariance controlling for age, sex, B-type natriuretic peptide, and SMI.Among the 316 patients, 133 (42.1%) were Normal, 31 (9.8%) Dynapenia, and 152 (48.1%) Sarcopenia. Unadjusted comparisons showed graded differences across the 3 groups for physical function, cognitive function, and activities of daily living, with the decreasing order being Normal > Dynapenia > Sarcopenia. After adjustment, differences between the Dynapenia and Sarcopenia groups were no longer significant, whereas Dynapenia remained lower than Normal for grip strength, walking speed, and phase angle.Dynapenia may represent a distinct phenotype with preserved muscle mass but reduced strength, influenced by comorbidities and systemic CVD effects. Identifying dynapenia could support phenotype-specific rehabilitation strategies, although further studies are needed to clarify the underlying mechanisms.","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"245-252"},"PeriodicalIF":1.4,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147963614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Implications of Myocardial T1 Mapping Parameters in Relation to Left Ventricular Characteristics in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy. 野生型转甲状腺蛋白淀粉样心肌病患者心肌T1定位参数与左心室特征的临床意义

IF 1.3 4区医学

International heart journal Pub Date : 2026-05-30 Epub Date: 2026-05-16 DOI: 10.1536/ihj.26-016

Toshiro Kitagawa, Kotaro Hamamoto, Daiki Okamoto, Yoshiharu Sada, Fuminari Tatsugami, Yukiko Nakano

引用次数: 0

Evaluation of Participant Characteristics and Short-Term Outcomes in a Community-Based Hypertension Awareness Event in Japan. 日本社区高血压认知活动参与者特征和短期结果评估

IF 1.3 4区医学

International heart journal Pub Date : 2026-05-30 Epub Date: 2026-05-16 DOI: 10.1536/ihj.26-054

Noriko Taguchi, Satoshi Yanagisawa, Kyoko Tsunekawa, Ryusuke Ota, Masayuki Suzuki, Eriko Miyagawa, Hikari Miyahara, Sayuri Takemoto, Toyoaki Murohara

引用次数: 0